A Phase I Trial of the Combination of the PARP Inhibitor ABT-888 With Intraperitoneal Floxuridine (FUDR) in Epithelial Ovarian, Primary Peritoneal and Fallopian Tube Cancers
Study identifier: NCT01749397
Full study details on clinicaltrials.gov
Name of PARP Inhibitor used in study:
Metastatic epithelial ovarian, primary peritoneal, or fallopian tube cancer for which standard curative measures do not exist, no prior PARP inhibitor.
Type of study:
Phase I study
21-day cycles with veliparib intravenously on days 1-10 and floxuridine intraperitoneal on days 3-5
Johns Hopkins University
Contact: Deborah K. Armstrong 410-955-8804 firstname.lastname@example.org
Principal Investigator: Deborah K. Armstrong
Contact: Andrea E. Wahner Hendrickson 507-284-2511 email@example.com
Page updated 06/13/13
Disclaimer: Health links are made available for educational purposes only. This information should not be interpreted as medical advice. All health information should be discussed with your health care provider. Please read our full disclaimer for more information.
This site has been made possible by a generous grant from Morphotek.